International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H.
Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia.
Kruse A, Abdel-Azim N, Kim HN, Ruan Y, Phan V, Ogana H, Wang W, Lee R, Gang EJ, Khazal S, Kim YM.
Int J Mol Sci. 2020 Feb 5;21(3):1054. doi: 10.3390/ijms21031054.
Liquid biopsy and minimal residual disease - latest advances and implications for cure.
Pantel K, Alix-Panabières C.
Nat Rev Clin Oncol. 2019 Jul;16(7):409-424. doi: 10.1038/s41571-019-0187-3.
Minimal Residual Disease in Acute Myeloid Leukemia.
Gomez-Arteaga A, Guzman ML.
Adv Exp Med Biol. 2018;1100:111-125. doi: 10.1007/978-3-319-97746-1_7.
Minimal Residual Disease in Acute Myeloid Leukemia.
Sung PJ, Luger SM.
Curr Treat Options Oncol. 2017 Jan;18(1):1. doi: 10.1007/s11864-017-0447-3.
Minimal residual disease in chronic lymphocytic leukaemia.
García Vela JA, García Marco JA.
Med Clin (Barc). 2018 Feb 23;150(4):144-149. doi: 10.1016/j.medcli.2017.06.067. Epub 2017 Aug 31.
Minimal residual disease in multiple myeloma: use of magnetic resonance imaging.
Hillengass J, Merz M, Delorme S.
Semin Hematol. 2018 Jan;55(1):19-21. doi: 10.1053/j.seminhematol.2018.02.001. Epub 2018 Feb 12.
Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?
Al-Sawaf O, Seymour JF, Kater AP, Fischer K.
Hematol Oncol Clin North Am. 2021 Aug;35(4):775-791. doi: 10.1016/j.hoc.2021.03.007. Epub 2021 May 15.
Minimal Residual Disease Detection by Flow Cytometry in Multiple Myeloma: Why and How?
Roshal M.
Semin Hematol. 2018 Jan;55(1):4-12. doi: 10.1053/j.seminhematol.2018.02.011. Epub 2018 Mar 9.
Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.
Fuda F, Chen W.
Curr Hematol Malig Rep. 2018 Dec;13(6):455-466. doi: 10.1007/s11899-018-0479-1.
